Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q1 2019 · 10-Q
Revenue—
Net Income-$750.83K-$750.83KN/M vs Q1 2018 EPS Diluted-$0.14-$0.14N/M vs Q1 2018 Operating Income-$882,516N/M Operating Cash Flow-$492,429N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Mar 31, 2019 · filed May 14, 2019 · 44 d after period end